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Abstract
This research work is devoted to the development of new additional criteria for the activity of inflammatory process in
sarcoidosis of respiratory organs. The objective is to assess the effectiveness of performed treatment of sarcoidosis of
respiratory organs by using low-cost highly-sensitive inflammatory markers.
Materials and methods. The study involved 68 patients with lung sarcoidosis before and after the three-month treatment. In
addition to general-clinical methods of examination, patients with sarcoidosis were also determined the levels of TNF-α and
CRP.
Results and their discussion. Patients with active lung sarcoidosis had 17.6 times (p<0.05) increased level of CRP in
bronchoalveolar lavage fluid and 9.0 times (p<0.05) increased levels in peripheral blood serum; the levels of TNF-α increased
by 4.98 times (p<0.05) in bronchoalveolar lavage fluid and by 3.2 times (p<0.05) in peripheral blood serum as compared
to the findings in the control group of patients. The study showed that in the group of patients, where the efficacy of the
prescribed therapy was noted, the level of CRP decreased by 2.76 times (p<0.05) in bronchoalveolar lavage fluid and
by 2.58 times (p<0.05) in peripheral blood serum, and the concentration of TNF-α decreased by 3.87 times (p<0.05) in
bronchoalveolar lavage fluid and by 2.06 times in peripheral blood serum as compared to the initial indices.
Conclusions. The decrease of TNF-α level in bronchoalveolar lavage fluid on the background of three-months treatment
correlated (r=0.89; p<0.05) to the changes in peripheral blood serum; at the same time the decrease of TNF-α level in
peripheral blood serum correlated (r=0.82; p<0.05) to the decrease of CRP in peripheral blood serum of patients with
sarcoidosis of respiratory organs.
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Problem statement and analysis of the
recent research
For more than a century of study and despite the rapid de-
velopment of medicine and the introduction of molecular-
and-biological methods of investigation into clinical practice,
sarcoidosis still remains a disease with unidentified etiology
[2, 6].
Many scientists assume that the specific immune response,
which manifests itself as sarcoidosis, develops as a result of
combined effect of genetic factors, environmental exposure
and infectious agents [7, 8].
Delayed-type hypersensitivity reaction is the basis of im-
munopathogenesis of sarcoidosis of respiratory organs. The
development of immune-type granulomas in sarcoidosis (be-
cause of imbalance of immunoregulatory cell subpopulation
and weakening of T-cellular component of immune system)
says for the supposition that this pathology is caused by im-
munological disorders due to the exposure to various environ-
mental factors which change the immune status or are caused
by already changed immune status [1].
Accumulation of inflammatory and immune cells in or-
gans and tissues is the initial stage that eventually leads to the
damage of lung parenchyma. In lungs, the key role is given
to alveolar macrophages which take part both in the inductive
and effector phase of immune response [3].
Chemokines and cytokines are important components of
pathogenesis in sarcoidosis, because these mediators lead to
alveolitis, granuloma formation and tissue damage.
Alveolar macrophages are the major cellular source of
TNF-α . They also produce growth factor which stimulates the
proliferation of myofibroblasts, fibroblasts and B-lymphocytes.
TNF-α is a non-specific, however, powerful pro-inflammatory
cytokine that synthesizes a wide range of immune cells. In
scientists’ opinion, TNF-α is a key cytokine which takes part
in the formation of granuloma in sarcoidosis (Fehrenbach
H. et al., 2003). It induces the synthesis of IL-1 and IL-6,
contributes to the increase of leukocytes mobility, vasoper-
meability of microcirculatory bloodstream and intensification
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of apoptosis. Japanese scientists demonstrated that TNF-α
is responsible for the overexpression of adhesive molecule-1
(Intracellular Adhesion Molecule-1 or ICAM-1) on alveolar
macrophages, and the development of inflammatory granulo-
mas is associated with the aggregation of macrophages. The
inhibition of TNF-α synthesis reduces the ability to form
granulomas [12].
In addition, IL-1 takes a major place among the products
of macrophage secretion. It attracts T-lymphocytes to the
inflammation site. Activation of T-helpers is an essential
condition for granuloma formation, as they play the key role
in pathophysiology of sarcoidosis.
Therefore, T-lymphocytes, namely Th1-cells, produce IL-
2, which activates differentiation of effector cells, stimulates
the release of factors for positive chemotaxis of monocytes
and proliferation of T-cells, which consequently infiltrate the
parenchyma of lungs, lymph nodes and other tissues affected
by sarcoidosis [14].
IL-2 is a powerful inducer of T-cell proliferation and IFN-
γ synthesis and plays the key role in immune response in sar-
coidosis. Moreover, some scientists think that the increase of
IL-2 and IFN-α level (cytokine, which promotesTh1 response)
in bronchoalveolar lavage fluid may be the early predictor of
inflammatory process and say for the sarcoidosis progression.
World scientific literature represents a range of studies which
demonstrate clear correlation between the concentration of
soluble IL-2 receptor and T-helpers. The increase of soluble
IL-2 receptor level in peripheral blood serum is an activity
marker in patients with sarcoidosis of respiratory organs and
extrathoracic damages (except Lofgren’s syndrome) [10, 11].
Increased release of cytokines, formed in macrophages
(IL-1, IL-6, IL-8, IL-15, TNF-α), and chemokines (MIP-
α , IL-16) contributes to the formation of sarcoid granuloma
and lung damage. Excessive production of fibrogenic cy-
tokines (TGF-α and related cytokines, PDGF and IGF-1) by
macrophages leads to the development of fibrosis [9, 13].
The process of sarcoid granuloma development may be
schematically divided into 3 stages:
1. Th-1 activation by antigen-presenting macrophages;
2. release of cytokines with diverse and cross functions;
3. accumulation of immunocompetent cells in sites of in-
flammation of affected organs.
Immune shifts in sarcoidosis on organ level lead to the de-
velopment of three relative (though, not obligate for a specific
patient) stages: alveolitis (lymphocytic infiltration) - granulo-
matosis (epithelioid-cellular granuloma) - fibrosis [4, 5].
Estimation of inflammatory process activity in sarcoidosis
is of great practical consequence, as it enables the clinician to
make personal prognosis for every patient, find adequate thera-
peutic approach and evaluate the effectiveness of administered
treatment. Determining the regularities of TNF-α dynamics in
bronchoalveolar lavage fluid and peripheral blood serum will
make it possible to better analyze the management of patients.
While its correlation with routine low-cost identification of
C-reactive protein will allow to maximally bring the process
closer to the primary medical care and make it cheaper.
Objective. The aim is to find additional criteria for inflam-
matory process activity in sarcoidosis of respiratory organs.
1. Materials and methods
We conducted in-depth instrumental examination of 68 pa-
tients with lung sarcoidosis before and after the three-month
treatment. The mean age of patients was (35.7±6.6) years. All
of them underwent in-patient treatment in the pulmonology
unit of the regional clinical phthisiopneumologic centre (Ivano-
Frankivsk).
The control group involved 16 apparently healthy individ-
uals.
All the patients underwent complete clinical examination
in accordance with the 3rd level of specialized pulmonologic
care in healthcare centres: general clinical and laboratory-
instrumental examination, including multispiral computed
tomography of thoracic organs and fibrobronchoscopy, as well
as, determining the levels of C-reactive protein and TNF-α in
bronchoalveolar lavage fluid and peripheral blood serum.
In the course of investigation, patients underwent fibro-
bronchoscopy with the help of ”Olympus BF-20” fiber-optic
bronchoscope (Japan) with simultaneous sampling of bron-
choalveolar lavage fluid and estimation of inflammatory changes
of tracheobronchial tree according to the generally established
procedure by J. Lemoine in the modification of H.I. Lukom-
skyi.
The level of TNF-α was identified by means of enzyme
immunoassay using ”StatFax 303 Plus” analyser and ”Hu-
man TNF-alpha ELISA” reagents produced by ”Diaclone”
(France).
The level of C-reactive protein was determined by semi-
quantitative method of latex particle agglutination test using
”Dialab” reagents kit (Austria).
Database creation and statistical analysis of the material
during the investigation period required implementation of
authoring software programs on the basis of Microsoft Ex-
cel (computation of relative values, their errors, stratification
analysis). Some investigation tasks were accomplished with
the use of licensed software suites for statistical analysis Mi-
crosoft Excel and Statistica 5.5, involving descriptive statistic
programs, geometrical mean values computation. (License
number 76487 - DEM - 2241066 - 104/8).
Multispiral computed tomography of thoracic organs was
performed using Toshiba Aquilion Prime scanner, with subse-
quent recording of findings on digital medium and assessing
the density of lung tissue by Hounsfield unit (HU) scale: when
the density of lung tissue in dynamics was less than 893.5
Hounsfield units the treatment was considered effective, but
if the density of lung tissue, as compared to initial indices,
exceeded 893.5 units the treatment was considered ineffective.
Complex therapy of patients with sarcoidosis of respira-
tory organs was carried out in accordance with the order of
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Ministry of Health Care of Ukraine #634 from September
08, 2014 ”On approval and implementation of medical and
technological documents on medical care standardization in
sarcoidosis”.
After three-month treatment the patients were divided into
2 subgroups according to their complaints, physical data and
the results of multispiral computed tomography of thoracic
organs:
• subgroup I - effective treatment (n=47) - patients with
positive clinic-radiologic presentation;
• subgroup II - ineffective treatment (n=21) - patients
whose symptoms either persisted or worsened, without
any positive radiologic dynamics.
2. Results of the investigation and their
discussion
The usability of CRP and TNF-α levels in bronchoalveolar
lavage fluid and peripheral blood serum as potential additional
markers for inflammatory process activity was evaluated by
comparing them to the data of multispiral computed tomog-
raphy of thoracic organs and clinical manifestations of the
disease.
The most frequent subjective manifestations of the pathol-
ogy were:
• cough - 52 (76.47%) patients, non-productive in most
cases - 37 (71.15%), and in 15 cases (28.85%) with
small quantity of mucoid sputum;
• dyspnea - 40 (58.82%) patients: in 26 (65%) cases it
was caused by strenuous physical activity; in 13 (32.5%)
cases it occurred with normal strenuous activity and in
1case (2.5%) patient’s physical activity was low;
• pain and chest discomfort - 6 (8.82%) patients;
• general weakness and rapid fatigability - 28 (41.17%)
patients.
Inflammatory process activity was assessed by identify-
ing the concentrations of C-reactive protein and TNF-α in
bronchoalveolar lavage fluid and peripheral blood serum.
It has been established that the level of C-reactive protein
in bronchoalveolar lavage fluid of patients with active lung
sarcoidosis (n=68) made up (28.34±2.45) mg/l before treat-
ment, that is 17.6 times higher as compared to the levels in
the control group (n=16) - (1.61±0.17) mg/l (p<0.05) (Fig.
1).
The level of TNF-α in bronchoalveolar lavage fluid at
the time of initial examination was (142.13±7.59) pg/ml and
exceeded the given index by 4.98 times as compared to the
control group of patients (Fig. 2) (p<0.05).
Simultaneously these parameters were identified in periph-
eral blood serum. The level of C-reactive protein in patients
with active lung sarcoidosis (n=68) was 9.0 times higher than
Figure 1. Level of C-reactive protein in patients with
sarcoidosis of respiratory organs before treatment (p<0.05).
Figure 2. Level of TNF-α in patients with sarcoidosis of
respiratory organs before treatment (p<0.05).
in apparently healthy individuals (n=16) (p<0.05), and made
up (47.63±2.33) mg/l (see Fig. 1). The level of TNF-α
was 3.2 times increased as compared to the control group
(90.75±5.34) pg/ml (p<0.05), and made up (290.41±8.27)
pg/ml (see Fig. 2).
In our opinion, the established correlations between the
increase in TNF-α and CRP levels in bronchoalveolar lavage
fluid (r=0.88; p<0.05) and between the increase of CRP levels
in bronchoalveolar lavage fluid and peripheral blood serum
(r=0.96; p<0.05) in activation/progression of the inflamma-
tory process in patients with sarcoidosis of respiratory organs
are especially valuable. These findings correspond to the data
obtained by multispiral computed tomography of thoracic
organs and obtained lung tissue density in Hounsfield units
(HU).
We have noticed the normalization/improvement of gen-
eral state and decrease/absence of cough, dyspnea and chest
pain in patients from subgroup I after the three-month treat-
ment.
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While in subgroup II dyspnea persisted/progressed in
17 patients (85.71%), cough appeared or worsened in 14
(66.67%) patients, chest pain persisted in 1 (4.76%) case
and 6 patients (28.57%) still complained of general weakness
and rapid fatigability.
In subgroup I (n=47) the level of C-reactive protein in
bronchoalveolar lavage fluid was (10.27±1.18) mg/l, that is
2.76 times lower as compared to the initial data (p<0.05).
And what is more, this index has also decreased in peripheral
blood serum (r=0.94; p<0.05) to (18.47±1.05) mg/l (p<0.05),
that was 2.58 times lower than before treatment (Fig. 1).
On the background of three-month treatment, the level
of TNF-α in bronchoalveolar lavage fluid has decreased by
3.87 times and made up (36.75±4.39) pg/ml (p<0.05). These
positive results correlated (r=0.89; p<0.05) with the changes
in peripheral blood serum, where the concentration of this
cytokine was (141.22±6.97) pg/ml, that was 2.06 times lower
than the initial data (p<0.05) (Fig. 1). At the same time the
decrease in the level of TNF-α in peripheral blood serum
correlated (r=0.82; p<0.05) with the decrease of CRP level in
peripheral blood serum of patients with sarcoidosis of respira-
tory organs.
Treatment was considered to be inadequate in subgroup
II (n=21), and the levels of C-reactive protein remained in-
creased in both bronchoalveolar lavage fluid and peripheral
blood serum and made up (31.86±2.64) mg/l (p<0.05), (55.15
±2.68) mg/l (p<0.05), respectively.
TNF-α , in patients with ineffective treatment, tended
to even increase: its concentration was 189.24±5.22 pg/ml
(p<0.05) in bronchoalveolar lavage fluid and 382.13±15.44
pg/ml (p<0.05) in peripheral blood serum (Table 1). The dy-
namics of C-reactive protein and TNF-α with both effective
and ineffective treatment corresponded to the data of general
clinical examinations, and was associated with clinical symp-
toms and changes in multispiral computed tomography of
thoracic organs and lung tissue density in Hounsfield units.
3. Conclusions
1. The characteristic symptoms of lung sarcoidosis activa-
tion requiring treatment are: onset of dyspnea; cough
that is accompanied by changes in lung tissue density
(according to the findings of MSCT of thoracic organs),
as compared to the initial data - 893.5 HU; increase
of CRP level in bronchoalveolar lavage fluid by 17.6
times (p<0.05) and by 9.0 times (p<0.05) in peripheral
blood serum; increase of TNF-α level in bronchoalveo-
lar lavage fluid by 4.98 times (p<0.05) and by 3.2 times
(p<0.05) in peripheral blood serum as compared to the
control group data.
2. The characteristic features of failure of three-month
treatment for lung sarcoidosis requiring escalation of
medication treatment regimens are: persistent and pro-
gressive dyspnea and cough, maintenance of high CRP
concentrations in bronchoalveolar lavage fluid (31.86
±2.64) mg/l (p<0.05) and in peripheral blood serum
(55.15±2.68) mg/l (p<0.05), as well as the levels of
TNF-α in bronchoalveolar lavage fluid and peripheral
blood serum which made up (189.24±5.22) pg/ml (p<0.05)
and 382.13±15.44 pg/ml (p<0.05) respectively.
3. Three-month treatment for lung sarcoidosis was con-
sidered to be effective when dyspnea and cough de-
creased, and the condition was associated with the de-
crease of lung tissue density below -893.5 HU (based
on MSCT of thoracic organs), and decrease of CRP
level by 2.76 times (p<0.05) in bronchoalveolar lavage
fluid and by 2.58 times (p<0.05) in peripheral blood
serum, decrease of TNF-α concentration by 3.87 times
(p<0.05) in bronchoalveolar lavage fluid and by 2.06
times in peripheral blood serum, as compared to the
initial data.
4. The decrease of TNF-α level in bronchoalveolar lavage
fluid, on the background of three-month treatment, cor-
related (r=0.89; p<0.05) with the changes in periph-
eral blood serum, while, at the same time the decrease
of TNF-α level in peripheral blood serum correlated
(r=0.82; p<0.05) with the decrease of CRP level in
peripheral blood serum of patients with sarcoidosis of
respiratory organs.
4. Prospects of future research
The study of dynamics of C-reactive protein and TNF-α in
patients with sarcoidosis of respiratory organs will make it
possible to assess the degree of local and systemic inflam-
mation, modify the treatment options and make individual
prognosis for every patient.
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